Tumor screening and clinical history are both helpful in identifying patients who may have LS, but the identification of heterozygous pathogenic or likely pathogenic (P/LP) variants in one of the MMR genes (or EPCAM) is the definitive diagnosis of LS2. The gene discussed is MRC1; the disease is neoplasm.